Prosensa Finds Path Forward For Drisapersen In DMD Drug Revival
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Dutch company received positive news for its development programs in the U.S., an encouraging sign for a disease space that has been flailing in recent months due to unclear clinical endpoints.